Cabio Biotech (Wuhan) Co., Ltd.
Shanghai Stock ExchangeTotal Valuation
Cabio Biotech (Wuhan) Co., Ltd. carries a market capitalization of 1.86B, placing it among publicly traded companies globally. Its enterprise value stands at 4.00B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 1.86B |
| Enterprise Value | 4.00B |
Share Statistics
Cabio Biotech (Wuhan) Co., Ltd. currently has 168.31M shares outstanding.
| Shares Outstanding | 168.31M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
Cabio Biotech (Wuhan) Co., Ltd. trades at a trailing price-to-earnings ratio of 25.51. The price-to-sales ratio is 6.97, and the price-to-book ratio stands at 5.62.
| PE Ratio | 25.51 |
| PS Ratio | 6.97 |
| PB Ratio | 5.62 |
| P/TBV Ratio | 2.63 |
| P/FCF Ratio | 21.80 |
| P/OCF Ratio | N/A |
Enterprise Valuation
On an enterprise value basis, Cabio Biotech (Wuhan) Co., Ltd. trades at an EV/EBITDA multiple of 23.94 and an EV/FCF ratio of 20.70. The EV/Sales ratio of 6.65 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 23.94 provides insight into valuation relative to core operating earnings.
| EV / Sales | 6.65 |
| EV / EBITDA | 23.94 |
| EV / EBIT | 23.94 |
| EV / FCF | 20.70 |
Financial Position
Cabio Biotech (Wuhan) Co., Ltd. maintains a current ratio of 4.76, meaning it holds 4.8x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 5.36, indicating elevated leverage, while an interest coverage ratio of 173.52 demonstrates strong ability to service its debt obligations.
| Current Ratio | 4.76 |
| Quick Ratio | 1.72 |
| Debt / Equity | 5.36 |
| Debt / EBITDA | 0.53 |
| Interest Coverage | 173.52 |
Financial Efficiency
Cabio Biotech (Wuhan) Co., Ltd. posts a return on equity of 24.11 and a return on invested capital of 8.96.
| Return on Equity (ROE) | 24.11 |
| Return on Assets (ROA) | 9.44 |
| Return on Invested Capital (ROIC) | 8.96 |
| Return on Capital Employed (ROCE) | 22.64 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 2.27 |
Taxes
Over the trailing twelve months, Cabio Biotech (Wuhan) Co., Ltd. has paid 24.76M in income taxes, reflecting an effective tax rate of 13.39.
| Income Tax | 24.76M |
| Effective Tax Rate | 13.39 |
Stock Price Statistics
Cabio Biotech (Wuhan) Co., Ltd.'s stock has declined approximately -55.73312% over the past 52 weeks. The 50-day moving average sits at 13.52, while the 200-day moving average is 19.59.
| Beta (5Y) | N/A |
| 52-Week Price Change | -55.73312% |
| 50-Day Moving Average | 13.52 |
| 200-Day Moving Average | 19.59 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Cabio Biotech (Wuhan) Co., Ltd. generated 601.49M in revenue and converted that into 164.27M in net income, yielding earnings per share of 0.96. EBITDA reached 167.04M, while operating income came in at 167.04M.
| Revenue | 601.49M |
| Gross Profit | 284.91M |
| Operating Income | 167.04M |
| Pretax Income | 184.95M |
| Net Income | 164.27M |
| EBITDA | 167.04M |
| EBIT | 167.04M |
| Earnings Per Share (EPS) | 0.96 |
Balance Sheet
Cabio Biotech (Wuhan) Co., Ltd. holds 292.69M in cash and equivalents against 87.79M in total debt, resulting in a net debt position of -195.11M. Total book value stands at 745.95M, with working capital of 639.02M providing operational flexibility.
| Cash & Cash Equivalents | 292.69M |
| Total Debt | 87.79M |
| Net Debt | -195.11M |
| Equity (Book Value) | 745.95M |
| Book Value Per Share | 4.48 |
| Working Capital | 639.02M |
Cash Flow
After subtracting -192.29M in capital expenditures, free cash flow totaled -192.29M - equivalent to -1.15 per share.
| Operating Cash Flow | N/A |
| Capital Expenditures | -192.29M |
| Free Cash Flow | -192.29M |
| FCF Per Share | -1.15 |
Margins
Cabio Biotech (Wuhan) Co., Ltd. operates with a gross margin of 47.37, reflecting its pricing power and cost economics. The operating margin of 27.77 and net profit margin of 27.31 provide insight into operational efficiency.
| Gross Margin | 47.37 |
| Operating Margin | 27.77 |
| Pretax Margin | 30.75 |
| Profit Margin | 27.31 |
| EBITDA Margin | 27.77 |
Dividends & Yields
The company's payout ratio of 0.62 indicates the proportion of earnings distributed to shareholders.
| Dividend Per Share | 0.01 |
| Dividend Yield | N/A |
| Payout Ratio | 0.62 |
| Shareholder Yield | -1.32 |
| FCF Yield | 4.59 |
Stock Splits
Cabio Biotech (Wuhan) Co., Ltd.'s most recent stock split took place on July 18, 2023 with a 5:7 split ratio.
| Last Split Date | 7/18/2023 |
| Split Ratio | 5:7 |
Scores
Cabio Biotech (Wuhan) Co., Ltd. posts an Altman Z-Score of 13.93, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 13.93 |